Get started
Author

Kenza Abouir

Observed name: Abouir, Kenza
ORCID: 0000-0002-4401-432X
Observed ORCID: 0000-0002-4401-432X
OpenAlex ID: A5014681148
Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
2021 · Kenza Abouir, Caroline F Samer, et al. · Frontiers in Pharmacology · 58
Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
2024 · Kenza Abouir, Nadia Exquis, et al. · Clinical Pharmacology & Therapeutics · 34
PDF
Dexamethasone exposure in normal‐weight and obese hospitalized COVID ‐19 patients: An observational exploratory trial
2022 · Kenza Abouir, Pauline Gosselin, et al. · Clinical and Translational Science · 12
PDF
The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID‐19 Patients: A Physiologically Based Pharmacokinetic Modeling Study
2024 · Jean Terrier, Kenza Abouir, et al. · Clinical Pharmacology & Therapeutics · 5
Improving CYP2C19 phenotyping using stereoselective omeprazole and 5‐hydroxy‐omeprazole metabolic ratios
2024 · Kenza Abouir, Emmanuel Varesio, et al. · Basic & Clinical Pharmacology & Toxicology · 4
PDF
Stereoselective separation of omeprazole and 5-hydroxy-omeprazole using dried plasma spots and a heart-cutting 2D-LC approach for accurate CYP2C19 phenotyping
2023 · Kenza Abouir, Caroline Samer, et al. · Journal of Chromatography B · 3
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia
2022 · Kenza Abouir, Alexandra Calmy, et al. · JAMA · 1
Stereoselective Determination of Omeprazole and 5‐Hydroxy‐Omeprazole in Dried Blood Spots for CYP2C19 Activity Assessment
2026 · Toon Hectors, Kenza Abouir, et al. · Basic & Clinical Pharmacology & Toxicology
PDF
Works count: 9
Citation count: 117
H-index: 4
I10-index: 3
Year
Topic
Type